JonesTrading Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Lina Kaminski maintains a Buy rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $52 to $56.
March 20, 2024 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JonesTrading analyst Lina Kaminski maintains a Buy rating on Crinetics Pharmaceuticals and raises the price target from $52 to $56.
The increase in the price target by JonesTrading reflects a positive outlook on Crinetics Pharmaceuticals' future performance. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100